Atea Pharmaceuticals (AVIR) Enterprise Value (2020 - 2026)

Atea Pharmaceuticals' Enterprise Value history runs 8 years deep, the most recent figure standing at -$256.0 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 39.83% year-over-year to -$256.0 million; the TTM figure through Mar 2026 stood at -$256.0 million (up 39.83% YoY), while the FY2025 annual figure was -$301.8 million, up 64.11% from the prior year.
• Enterprise Value for Q1 2026 stood at -$256.0 million, up from -$301.8 million in the prior quarter.
• The five-year high for Enterprise Value was -$256.0 million in Q1 2026, with the low at -$919.8 million in Q1 2024.
• The 5-year median for Enterprise Value is -$620.5 million (2023), against an average of -$592.6 million.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value sank 48.23% in 2024, then surged 64.11% in 2025.
• Atea Pharmaceuticals' Enterprise Value stood at -$646.7 million in 2022, then advanced by 10.61% to -$578.1 million in 2023, then plunged by 45.48% to -$841.0 million in 2024, then surged by 64.11% to -$301.8 million in 2025, then increased by 15.18% to -$256.0 million in 2026.
• Business Quant data shows AVIR's Enterprise Value at -$256.0 million in Q1 2026, -$301.8 million in Q4 2025, and -$329.3 million in Q3 2025.